Prognostic significance of EZH2 expression in patients with digestive cancers: a meta-analysis

Wei Wang, Feng Wang, Guangquan Zong, Renmin Liu, Yufei Zhang, Yang Luan, Lin Xu, Ji Xuan
2015 Int J Clin Exp Med   unpublished
Enhancer of zeste 2 (EZH2), a key component of polycomb repressive complex 2 (PRC2), was of great importance in human cancer pathogenesis. Various studies examined the relationship between EZH2 overexpression with the clinical outcome in patients with digestive cancers, but yielded inconsistent results. Methods: Electronic databases updated to January 2015 were searched to find relevant studies. A meta-analysis was conducted with eligible studies which quantitatively evaluated the relationship
more » ... d the relationship between EZH2 overexpression and survival of patients with digestive cancers. Survival data were aggregated and quantitatively analyzed. Results: We performed a meta-analysis of 10 studies (n = 1,461 patients) that evaluated the correlation between EZH2 overex-pression and survival in patients with digestive cancers. Combined hazard ratios suggested that EZH2 overexpres-sion was associated with poor prognosis of overall survival (HR = 1.54, 95% CI: 1.27-1.81) in patients with esopha-geal cancer. In the stratified analysis, no significantly risks were found among gastric cancer (HR = 0.66, 95% CI: 0.16-1.15) and colorectal cancer (HR = 0.91, 0.63-1.19), indicating EZH2 was not an indicator of poor prognosis in gastric cancer or colorectal cancer. Conclusions: EZH2 overexpression indicates a poor prognosis for patients with esophageal cancer, but not among gastric cancer or colorectal cancer.